company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
"Millendo Therapeutics, Inc.",MLND,,0001544227,2011.0,Q2,2011-07-01,2011-09-30,2012-11-13 13:25:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,370000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2011.0,Q2,2011-07-01,2011-09-30,2012-11-13 13:25:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,404000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2011.0,Q2,2011-07-01,2011-09-30,2012-11-13 13:25:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,774000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2011.0,Q2,2011-07-01,2011-09-30,2012-11-13 13:25:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-774000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2011.0,Q2,2011-07-01,2011-09-30,2012-11-13 13:25:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-774000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2011.0,Q2,2011-07-01,2011-09-30,2012-11-13 13:25:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-774000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2011.0,Q2,2011-07-01,2011-09-30,2012-11-13 13:25:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-774000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2011.0,Q2,2011-07-01,2011-09-30,2012-11-13 13:25:18+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,101000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2011.0,Q2,2011-07-01,2011-09-30,2012-11-13 13:25:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-875000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2011.0,Q2,2011-07-01,2011-09-30,2012-11-13 13:25:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1000000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2011.0,Q2,2011-07-01,2011-09-30,2012-11-13 13:25:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.89
"Millendo Therapeutics, Inc.",MLND,,0001544227,2011.0,Q2,2011-07-01,2011-09-30,2012-11-13 13:25:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1000000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2011.0,Q2,2011-07-01,2011-09-30,2012-11-13 13:25:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.89
"Millendo Therapeutics, Inc.",MLND,,0001544227,2011.0,Q2,2011-07-01,2011-09-30,2012-11-13 13:25:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,979000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2011.0,Q2,2011-07-01,2011-09-30,2012-11-13 13:25:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.89
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 13:19:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2020000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 13:19:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,946000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 13:19:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2966000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 13:19:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2966000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 13:19:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2966000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 13:19:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2966000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 13:19:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2966000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 13:19:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-2966000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 13:19:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1400000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 13:19:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.14
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 13:19:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1400000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 13:19:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.14
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 13:19:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1383000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q1,2012-01-01,2012-03-31,2013-05-15 13:19:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.14
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q2,2012-04-01,2012-06-30,2012-08-14 13:36:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1883000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q2,2012-04-01,2012-06-30,2012-08-14 13:36:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1351000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q2,2012-04-01,2012-06-30,2012-08-14 13:36:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3234000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q2,2012-04-01,2012-06-30,2012-08-14 13:36:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3234000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q2,2012-04-01,2012-06-30,2012-08-14 13:36:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3234000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q2,2012-04-01,2012-06-30,2012-08-14 13:36:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3234000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q2,2012-04-01,2012-06-30,2012-08-14 13:36:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3234000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q2,2012-04-01,2012-06-30,2012-08-14 13:36:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3234000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q2,2012-04-01,2012-06-30,2012-08-14 13:36:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1500000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q2,2012-04-01,2012-06-30,2012-08-14 13:36:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.09
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q2,2012-04-01,2012-06-30,2012-08-14 13:36:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1500000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q2,2012-04-01,2012-06-30,2012-08-14 13:36:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.09
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q2,2012-04-01,2012-06-30,2012-08-14 13:36:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1548000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q2,2012-04-01,2012-06-30,2012-08-14 13:36:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.09
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q3,2012-07-01,2012-09-30,2012-11-13 13:25:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1525000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q3,2012-07-01,2012-09-30,2012-11-13 13:25:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1595000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q3,2012-07-01,2012-09-30,2012-11-13 13:25:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3120000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q3,2012-07-01,2012-09-30,2012-11-13 13:25:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3120000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q3,2012-07-01,2012-09-30,2012-11-13 13:25:18+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,2000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q3,2012-07-01,2012-09-30,2012-11-13 13:25:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q3,2012-07-01,2012-09-30,2012-11-13 13:25:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3118000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q3,2012-07-01,2012-09-30,2012-11-13 13:25:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3118000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q3,2012-07-01,2012-09-30,2012-11-13 13:25:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3118000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q3,2012-07-01,2012-09-30,2012-11-13 13:25:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3118000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q3,2012-07-01,2012-09-30,2012-11-13 13:25:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,7400000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q3,2012-07-01,2012-09-30,2012-11-13 13:25:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.42
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q3,2012-07-01,2012-09-30,2012-11-13 13:25:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,7400000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q3,2012-07-01,2012-09-30,2012-11-13 13:25:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.42
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q3,2012-07-01,2012-09-30,2012-11-13 13:25:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,7438000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q3,2012-07-01,2012-09-30,2012-11-13 13:25:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.42
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1778000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2431000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4209000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4209000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,17000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,17000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4192000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4192000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4192000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4192000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,5800000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.32
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,5800000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.32
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,5810000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.32
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q1,2013-01-01,2013-03-31,2013-05-15 13:19:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2495000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q1,2013-01-01,2013-03-31,2013-05-15 13:19:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2680000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q1,2013-01-01,2013-03-31,2013-05-15 13:19:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5175000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q1,2013-01-01,2013-03-31,2013-05-15 13:19:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5175000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q1,2013-01-01,2013-03-31,2013-05-15 13:19:06+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,18000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q1,2013-01-01,2013-03-31,2013-05-15 13:19:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,18000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q1,2013-01-01,2013-03-31,2013-05-15 13:19:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5157000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q1,2013-01-01,2013-03-31,2013-05-15 13:19:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5157000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q1,2013-01-01,2013-03-31,2013-05-15 13:19:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5157000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q1,2013-01-01,2013-03-31,2013-05-15 13:19:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5157000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q1,2013-01-01,2013-03-31,2013-05-15 13:19:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,13200000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q1,2013-01-01,2013-03-31,2013-05-15 13:19:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.39
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q1,2013-01-01,2013-03-31,2013-05-15 13:19:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,13200000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q1,2013-01-01,2013-03-31,2013-05-15 13:19:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.39
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q1,2013-01-01,2013-03-31,2013-05-15 13:19:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,13345000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q1,2013-01-01,2013-03-31,2013-05-15 13:19:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.39
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q2,2013-04-01,2013-06-30,2013-08-13 10:45:12+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3445000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q2,2013-04-01,2013-06-30,2013-08-13 10:45:12+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2576000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q2,2013-04-01,2013-06-30,2013-08-13 10:45:12+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6021000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q2,2013-04-01,2013-06-30,2013-08-13 10:45:12+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-6021000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q2,2013-04-01,2013-06-30,2013-08-13 10:45:12+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,25000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q2,2013-04-01,2013-06-30,2013-08-13 10:45:12+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,25000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q2,2013-04-01,2013-06-30,2013-08-13 10:45:12+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5996000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q2,2013-04-01,2013-06-30,2013-08-13 10:45:12+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5996000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q2,2013-04-01,2013-06-30,2013-08-13 10:45:12+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5996000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q2,2013-04-01,2013-06-30,2013-08-13 10:45:12+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5996000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q2,2013-04-01,2013-06-30,2013-08-13 10:45:12+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,16700000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q2,2013-04-01,2013-06-30,2013-08-13 10:45:12+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.36
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q2,2013-04-01,2013-06-30,2013-08-13 10:45:12+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,16700000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q2,2013-04-01,2013-06-30,2013-08-13 10:45:12+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.36
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q2,2013-04-01,2013-06-30,2013-08-13 10:45:12+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,16869000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q2,2013-04-01,2013-06-30,2013-08-13 10:45:12+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.36
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q3,2013-07-01,2013-09-30,2013-11-13 16:30:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3663000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q3,2013-07-01,2013-09-30,2013-11-13 16:30:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3262000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q3,2013-07-01,2013-09-30,2013-11-13 16:30:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6925000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q3,2013-07-01,2013-09-30,2013-11-13 16:30:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-6925000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q3,2013-07-01,2013-09-30,2013-11-13 16:30:51+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,34000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q3,2013-07-01,2013-09-30,2013-11-13 16:30:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,34000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q3,2013-07-01,2013-09-30,2013-11-13 16:30:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6891000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q3,2013-07-01,2013-09-30,2013-11-13 16:30:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6891000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q3,2013-07-01,2013-09-30,2013-11-13 16:30:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6891000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q3,2013-07-01,2013-09-30,2013-11-13 16:30:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6891000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q3,2013-07-01,2013-09-30,2013-11-13 16:30:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,17200000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q3,2013-07-01,2013-09-30,2013-11-13 16:30:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.4
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q3,2013-07-01,2013-09-30,2013-11-13 16:30:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,17200000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q3,2013-07-01,2013-09-30,2013-11-13 16:30:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.4
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q3,2013-07-01,2013-09-30,2013-11-13 16:30:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,17048000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q3,2013-07-01,2013-09-30,2013-11-13 16:30:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.4
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3729000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7284000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11013000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11013000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,13000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,13000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11000000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11000000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11000000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11000000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,16100000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.65
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,16100000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.65
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,16160000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.65
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:12:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2998000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:12:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4652000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:12:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7650000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:12:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7650000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:12:27+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-57000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:12:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-57000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:12:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7707000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:12:27+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-107000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:12:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7814000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:12:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7814000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:12:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7814000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:12:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19100000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:12:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.41
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:12:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,19100000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:12:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.41
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:12:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19214000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 16:12:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.41
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5061000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4534000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9595000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9595000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,27000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-27000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9622000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-271000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9893000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9893000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9893000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,23600000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.42
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,23600000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.42
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,23546000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q2,2014-04-01,2014-06-30,2015-08-10 16:09:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.42
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7074000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5325000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12399000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12399000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,25000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-25000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12424000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-499000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12923000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12923000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12923000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,23900000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.54
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,23900000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.54
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,23766000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 16:38:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.54
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11016000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7273000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18289000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18289000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-52000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-69000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1461000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1478000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19767000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,877000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18890000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18890000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18890000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,22600000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.82
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,22600000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.82
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,22647000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.82
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,15000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,15000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,35000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,35000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-20000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11046000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5747000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16793000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-16813000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-44000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-437000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-393000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-17206000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17206000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17206000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17206000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,26500000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.65
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,26500000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.65
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,26588000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 16:20:58+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.65
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,30000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,30000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,116000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,116000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-86000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13067000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4021000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17088000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17174000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-101000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-417000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-316000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-17490000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17490000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17490000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17490000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,27300000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.64
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,27300000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.64
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,27198000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q2,2015-04-01,2015-06-30,2016-08-04 16:10:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.64
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,940000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,940000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-865000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12909000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3998000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16907000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17772000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-141000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-291000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-150000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-17922000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17922000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17922000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17922000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,27200000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.66
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,27200000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.66
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,27267000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 16:15:04+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.66
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,157000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,157000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1158000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1158000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-1001000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14572000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4667000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19239000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-20240000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,286000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-1125000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1125000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-286000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-20526000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,75000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-20601000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-20601000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-20601000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,27100000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.75
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,27100000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.75
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,27085000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.75
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,146000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,146000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1176000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1176000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-1030000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14454000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5955000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20409000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21439000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-174000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-391000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-27000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-244000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21683000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,75000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21758000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21758000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-21758000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,27200000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.8
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,27200000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.8
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,27301000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 16:27:17+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.8
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,197000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,197000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1559000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1559000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-1362000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12612000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4990000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17602000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18964000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-162000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-364000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-33000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-235000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19199000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,92000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19291000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19291000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19291000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,35700000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.54
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,35700000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.54
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,35568000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2016.0,Q3,2016-07-01,2016-09-30,2017-11-02 16:07:22+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.54
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,63000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,63000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,269000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,269000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-206000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7129000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5764000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1488000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14381000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14587000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-182000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-421000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-60000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-299000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14886000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,9000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14895000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14895000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14895000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,35500000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.42
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,35500000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.42
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,35642000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q1,2017-01-01,2017-03-31,2018-05-03 16:59:09+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.42
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,84000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,84000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,274000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,274000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-190000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10751000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4997000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,2000000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17748000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17930000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-186000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-454000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,25000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-243000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18173000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,13000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18186000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18186000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18186000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,35700000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.51
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,35700000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.51
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,35664000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:07:08+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.51
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,56000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,56000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,29000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,29000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,27000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5056000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4016000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,361000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9433000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9406000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-193000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-140000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,50000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9356000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,11000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9367000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9367000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9367000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,36000000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.26
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,36000000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.26
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,35687000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q3,2017-07-01,2017-09-30,2018-11-09 17:24:02+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.26
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,-203000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,-203000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,-572000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,-572000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,369000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,-16980000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,63593000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-3849000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,42764000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-42403000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,849000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1015000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,66000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,232000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-42171000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-33000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-42138000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-42138000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-8000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-42130000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,300000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-320.62
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,300000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-320.62
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,262823.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-320.62
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1619000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2769000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4388000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4388000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,9000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-7000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4386000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4386000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4386000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-125000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4261000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,700000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-6.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,700000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-6.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,710390.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q1,2018-01-01,2018-03-31,2019-05-15 07:23:37+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-6.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3935000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3871000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7806000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7806000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-54000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-31000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-85000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7891000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7891000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7891000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-355000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7536000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,700000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-10.61
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,700000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-10.61
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,710390.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q3,2018-07-01,2018-09-30,2019-11-13 07:22:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-10.61
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5109000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4585000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9694000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9694000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-95000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-69000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-164000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9858000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9858000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9858000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,691000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10549000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1500000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,5.85
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1500000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,5.85
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1547051.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,5.85
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 07:36:34+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4453000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 07:36:34+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6204000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 07:36:34+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10657000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 07:36:34+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10657000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 07:36:34+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,315000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 07:36:34+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-24000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 07:36:34+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,291000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 07:36:34+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10366000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 07:36:34+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10366000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 07:36:34+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10366000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 07:36:34+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10366000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 07:36:34+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,13300000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 07:36:34+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.78
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 07:36:34+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,13300000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 07:36:34+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.78
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 07:36:34+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,13357999.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 07:36:34+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.78
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q2,2019-04-01,2019-06-30,2019-08-12 06:12:24+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4179000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q2,2019-04-01,2019-06-30,2019-08-12 06:12:24+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5981000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q2,2019-04-01,2019-06-30,2019-08-12 06:12:24+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10160000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q2,2019-04-01,2019-06-30,2019-08-12 06:12:24+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10160000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q2,2019-04-01,2019-06-30,2019-08-12 06:12:24+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,313000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q2,2019-04-01,2019-06-30,2019-08-12 06:12:24+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-24000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q2,2019-04-01,2019-06-30,2019-08-12 06:12:24+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,289000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q2,2019-04-01,2019-06-30,2019-08-12 06:12:24+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9871000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q2,2019-04-01,2019-06-30,2019-08-12 06:12:24+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9871000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q2,2019-04-01,2019-06-30,2019-08-12 06:12:24+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9871000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q2,2019-04-01,2019-06-30,2019-08-12 06:12:24+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9871000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q2,2019-04-01,2019-06-30,2019-08-12 06:12:24+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,13300000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q2,2019-04-01,2019-06-30,2019-08-12 06:12:24+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.74
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q2,2019-04-01,2019-06-30,2019-08-12 06:12:24+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,13300000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q2,2019-04-01,2019-06-30,2019-08-12 06:12:24+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.74
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q2,2019-04-01,2019-06-30,2019-08-12 06:12:24+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,13379842.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q2,2019-04-01,2019-06-30,2019-08-12 06:12:24+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.74
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4443000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7308000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11751000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11751000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,238000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-119000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,119000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11632000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11632000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11632000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11632000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,13400000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.87
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,13400000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.87
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,13420614.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q3,2019-07-01,2019-09-30,2019-11-13 07:22:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.87
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4481000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8350000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12831000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12831000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,172000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-40000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,132000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12699000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12699000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12699000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12699000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,13700000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.86
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,13700000.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.86
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,13706744.0
"Millendo Therapeutics, Inc.",MLND,,0001544227,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.86
